Quadrant Capital Group LLC Stoke Therapeutics, Inc. Transaction History

Quadrant Capital Group LLC

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 14, 2023	SELL	$3.78 - $11.99 $4,626 - $14,675	-1,224 Reduced 84.71%	221 $0
Q1 2023 May 11, 2023	BUY	$7.65 - $10.38 $8,254 - $11,200	1,079 Added 294.81%	1,445 $12,000
Q4 2022 Feb 10, 2023	BUY	$7.07 - $15.69 $2,587 - $5,742	366 New	366 $3,000
Q2 2022 Aug 09, 2022	SELL	$10.36 - $23.93 $1,170 - $2,704	-113 Closed	0 $0
Q1 2022 May 06, 2022	BUY	$17.19 - $26.1 $1,942 - $2,949	113 New	113 $2,000

123

57.6M

9.3K

35.2K

Ticker STOK
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 39,419,300
Market Cap $474M
Description
Stoke Therapeutics, Inc., an early-stage biopharmaceutical company, develops novel antisense oligonucleotide (ASO) medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary Targeted Augmentation of Nuclear Gene Output to design ASOs to precisely upregulate protein expression. I...

Get notified when there are updates to the investment portfolio of Quadrant Capital Group LLC, based on Form 13F filings with the SEC.

Stay updated on Quadrant Capital Group LLC with notifications on news.